Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | CA4 | P22748 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19948059 | 1.00 | CYP2D6 (0.39) | CYP2D6SLC6A2SLC6A4SLC6A3CA1 | |
| SCHEMBL25409001 | 0.84 | CHRNA7 (0.38) | CYP2D6SLC6A2SLC6A4SLC6A3CHRNA7 | |
| SCHEMBL28003047 | 0.84 | CHRNA7 (0.38) | CYP2D6SLC6A2SLC6A4SLC6A3CHRNA7 | |
| SCHEMBL3196435 | 0.84 | CHRNA7 (0.38) | CYP2D6SLC6A2SLC6A4SLC6A3CHRNA7 | |
| SCHEMBL20768868 | 0.82 | CA1 (0.39) | CYP2D6SLC6A2SLC6A4SLC6A3CA1 | |
| SCHEMBL1715039 | 0.82 | CA1 (0.39) | CYP2D6SLC6A2SLC6A4SLC6A3CA1 | |
| SCHEMBL8391746 | 0.81 | PARP1 (0.50) | CYP2D6SLC6A2SLC6A4SLC6A3CA1 | |
| SCHEMBL8391745 | 0.81 | PARP1 (0.50) | CYP2D6SLC6A2SLC6A4SLC6A3CA1 | |
| SCHEMBL3494643 | 0.80 | CA1 (0.52) | SLC6A2SLC6A4SLC6A3CA1CA2 | |
| SCHEMBL2419861 | 0.80 | CA1 (0.52) | SLC6A2SLC6A4SLC6A3CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | disclosed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| US-10125134-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP2D6 3803/4885SLC6A2 4813/4885SLC6A4 4807/4885 |
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CYP2D6 3803/4885SLC6A2 4813/4885SLC6A4 4807/4885 |
| US-20200262837-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP2D6 3803/4885SLC6A2 4813/4885SLC6A4 4807/4885 |
| US-10125134-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CYP2D6 3803/4885SLC6A2 4813/4885SLC6A4 4807/4885 |
| US-10689377-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CYP2D6 3803/4885SLC6A2 4813/4885SLC6A4 4807/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP2D6 3803/4885SLC6A2 4813/4885SLC6A4 4807/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP2D6 3803/4885SLC6A2 4813/4885SLC6A4 4807/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP2D6 3803/4885SLC6A2 4813/4885SLC6A4 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.